At present, our company conducts detailed comparison and analysis based on the nucleic acid sequence of the mutation site of the Omicron mutant strain published by the GISAID database and the recognition epitope of the specific anti-N protein antibody used in our Coronavirus antigen rapid test products. The analysis results showed that the mutation site of the Omicron mutant strain did not affect the antigen detection of coronavirus antigen rapid detection reagent developed, produced and sold by our company. Our company’s Testsealabs COVID-19 Antigen Rapid Test can effectively cover the new coronavirus Omicron (B.1.1529) mutant strain. However, since it is currently impossible to obtain specimens for verification, subsequent verification tests are required in the laboratory. Our company has verified the detection performance of coronavirus antigen rapid test developed by our